Kadence Bio

No open roles listed
Data updated Nov 21, 2026Full reportReport a mistake

Facts

as of Nov 21, 2026

Kadence Bio is a clinical stage therapeutics company whose mission is to develop innovative therapeutics that address critical unmet needs in sexual and mental health. We are developing the FDA-approved treatment for premature ejaculation.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Products

Products →

Kadence Bio has 2 clinical trials on record, 1 under way.

Clinical trials
Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Out…
phase 2 · under way · 40 participants · Premature Ejaculation
Dec 2025
A Phase I Study to Investigate KH-001 in Healthy Males
phase 1 · completed · 82 participants · Healthy Male Volunteers
Nov 2023
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices